JP2005507365A5 - - Google Patents

Download PDF

Info

Publication number
JP2005507365A5
JP2005507365A5 JP2002573735A JP2002573735A JP2005507365A5 JP 2005507365 A5 JP2005507365 A5 JP 2005507365A5 JP 2002573735 A JP2002573735 A JP 2002573735A JP 2002573735 A JP2002573735 A JP 2002573735A JP 2005507365 A5 JP2005507365 A5 JP 2005507365A5
Authority
JP
Japan
Prior art keywords
alkyl
carbon atoms
halogen
substituted
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002573735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005507365A (ja
JP4223287B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/001508 external-priority patent/WO2002074726A2/en
Publication of JP2005507365A publication Critical patent/JP2005507365A/ja
Publication of JP2005507365A5 publication Critical patent/JP2005507365A5/ja
Application granted granted Critical
Publication of JP4223287B2 publication Critical patent/JP4223287B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002573735A 2001-01-22 2002-01-22 新規な化合物及び製薬上許容し得るそれらの塩並びにそれらを用いた薬剤組成物 Expired - Fee Related JP4223287B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26265101P 2001-01-22 2001-01-22
US26719601P 2001-02-08 2001-02-08
US30614001P 2001-07-19 2001-07-19
PCT/US2002/001508 WO2002074726A2 (en) 2001-01-22 2002-01-22 Aniline derivatives useful as phosphodiesterase 4 inhibitors

Publications (3)

Publication Number Publication Date
JP2005507365A JP2005507365A (ja) 2005-03-17
JP2005507365A5 true JP2005507365A5 (2) 2008-02-21
JP4223287B2 JP4223287B2 (ja) 2009-02-12

Family

ID=27401532

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002573735A Expired - Fee Related JP4223287B2 (ja) 2001-01-22 2002-01-22 新規な化合物及び製薬上許容し得るそれらの塩並びにそれらを用いた薬剤組成物

Country Status (23)

Country Link
EP (1) EP1353907A2 (2)
JP (1) JP4223287B2 (2)
KR (1) KR100856622B1 (2)
CN (1) CN100378075C (2)
AU (1) AU2002303078B2 (2)
BG (1) BG108003A (2)
BR (1) BR0206943A (2)
CA (1) CA2435847A1 (2)
CL (1) CL2004001165A1 (2)
CZ (1) CZ20031986A3 (2)
EE (1) EE05362B1 (2)
HR (1) HRP20030662A2 (2)
HU (1) HUP0302793A3 (2)
IL (1) IL156958A0 (2)
MA (1) MA25996A1 (2)
MX (1) MXPA03006519A (2)
NO (1) NO329548B1 (2)
NZ (1) NZ527081A (2)
PL (1) PL373301A1 (2)
SK (1) SK9152003A3 (2)
WO (1) WO2002074726A2 (2)
YU (1) YU57603A (2)
ZA (1) ZA200305623B (2)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
MXPA03007261A (es) * 2001-02-14 2006-03-09 Abbott Lab Moduladores del receptor de glucocorticoides.
DE60325984D1 (de) 2002-07-19 2009-03-12 Memory Pharmaceutical Corp 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren
AU2003256616B2 (en) * 2002-07-19 2009-08-27 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs
CA2506297A1 (en) * 2002-11-19 2004-06-03 Memory Pharmaceuticals Corporation Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors
AU2003286024A1 (en) * 2002-11-22 2004-06-18 Daniel Dube Use of phosphodiesterase-4 inhibitors as enhancers of cognition
ES2282701T3 (es) * 2002-12-27 2007-10-16 H. Lundbeck A/S Derivados de 1,2,4-triaminobenceno utiles para tratar trastornos del sistema nervioso central.
FR2856595B1 (fr) * 2003-06-27 2008-05-30 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de deficits cognitifs.
JP2007504201A (ja) 2003-09-05 2007-03-01 アルタナ ファルマ アクチエンゲゼルシャフト 真性糖尿病の治療のためのpde4阻害剤の使用
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
MX2007000480A (es) 2004-07-15 2007-03-29 Japan Tobacco Inc Compuesto de benzamida fusionado e inhibidor de actividad de receptor de vainilloide 1.
US20070287716A1 (en) * 2004-10-28 2007-12-13 Hu Essa H Pyrimidine and Quinoline Potentiators of Metabotropic Glutamate Receptors
EP1874308A1 (en) 2005-03-08 2008-01-09 Nycomed GmbH Roflumilast for the treatment of diabetes mellitus
JP2008543781A (ja) * 2005-06-10 2008-12-04 メモリー・ファーマシューティカルズ・コーポレイション ホスフオジエステラーゼ4阻害剤
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
US7906508B2 (en) 2005-12-28 2011-03-15 Japan Tobacco Inc. 3,4-dihydrobenzoxazine compounds and inhibitors of vanilloid receptor subtype 1 (VRI) activity
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2110375A1 (en) * 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
WO2010041449A1 (ja) * 2008-10-09 2010-04-15 国立大学法人 岡山大学 Rxr作動性物質を有効成分とする抗アレルギー剤
HRP20191460T1 (hr) * 2009-06-12 2019-11-15 Abivax Spojevi korisni za liječenje raka
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
SI2440547T1 (sl) 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
JP6023926B2 (ja) 2010-02-12 2016-11-09 株式会社AskAt 認知症治療のための5−ht4受容体アゴニスト
WO2013118855A1 (ja) 2012-02-09 2013-08-15 塩野義製薬株式会社 複素環および炭素環誘導体
CN102603676B (zh) * 2012-02-20 2014-02-12 徐江平 一种能避免呕吐反应的磷酸二酯酶4抑制剂
CA2859842C (en) * 2012-03-14 2016-11-08 Sinochem Corporation Substitute diphenylamine compounds use thereof as antitumor agents
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
CN105530938B (zh) 2013-07-05 2019-10-22 Abivax公司 用于治疗由逆转录病毒引起的疾病的化合物
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
CN121609673A (zh) * 2026-02-02 2026-03-06 五邑大学 一种pde4抑制剂及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6971894A (en) * 1993-05-27 1994-12-20 Smithkline Beecham Laboratoires Pharmaceutiques Anti-arrhythmic n-substituted 3-benzazepines or isoquinolines
JPH07206789A (ja) * 1993-09-01 1995-08-08 Taisho Pharmaceut Co Ltd コンブレタスタチン類縁化合物
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
FR2729142A1 (fr) * 1995-01-06 1996-07-12 Smithkline Beecham Lab Nouvelles amines heterocycliques, leur procede de preparation et leur utilisation en tant que medicaments et notamment en tant qu'agents anti-arythmiques
CA2295106C (en) * 1997-06-24 2007-03-13 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
JP4649046B2 (ja) * 1999-05-21 2011-03-09 ブリストル−マイヤーズ スクイブ カンパニー キナーゼのピロロトリアジン阻害剤
EP1116711B1 (de) * 1999-12-18 2005-12-14 Wella Aktiengesellschaft 2-Aminoalkyl-1,4-diaminobenzol-Derivate und diese Verbindungen enthaltende Färbemittel

Similar Documents

Publication Publication Date Title
JP2005507365A5 (2)
AU751453C (en) Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use
RU2084453C1 (ru) Способ получения ароматических производных или их солей с органическими или неорганическими кислотами или их рацематов
JPWO1994014769A1 (ja) N−置換インドール誘導体
JPH10504530A (ja) Pde iv インヒビターとして有用なトリ置換フェニル誘導体
WO1990001936A1 (en) 3-(aminopropyl)methyl phosphinic acid as a therapeutic agent and intermediates in its synthesis
JPH07509219A (ja) H↓3受容体アンタゴニストとしての4−[4’−ピペリジニルまたは3’−ピロリジニル]置換イミダゾールおよび治療上のその使用方法
JP2001502712A (ja) 束縛されたソマトスタチン・アゴニスト及びアンタゴニスト
AU2017209023A1 (en) 2-oxindole compounds
US20030176421A1 (en) Prokinetic agents for treating gastric hypomotility and related disorders
ZA200205706B (en) Dehydroamino acids.
CN1137753A (zh) 作为胆碱能受体激动剂和拮抗剂的阿吡巴替丁及其衍生物
AU2025223941A1 (en) Compounds
PT77855B (en) Pyridine derivatives
US20140148432A1 (en) Compounds for the Treatment of Neurological Disorders
JP2000198734A (ja) 胃運動性減弱および関連疾患の治療のための運動性増強薬
JPH0578316A (ja) 置換n−フエニルピペリジン
WO1996031470A1 (en) Novel heterocyclic compounds
DK2303264T3 (en) METHODS FOR TREATING ALPHA-ADRENERG-MEDIATED CONDITIONS USING IMIDAZOLINE DERIVATIVES
JP2005527518A (ja) 新規なカルコン(chalcone)誘導体とその使用
JPS6157563A (ja) 5―オキシピリミジノン誘導体
JP3426242B2 (ja) ジアザシクロアルカンアルキルスルホンアミド誘導体
JP3499569B2 (ja) 新規複素環式化合物
JPS6048503B2 (ja) 新規な1−フエニル−2−アミノエタノ−ル誘導体
JP3332929B2 (ja) ある種の架橋4−フェニル−2−アミノメチルイミダゾール:新しいドパミン受容体サブタイプ特異的リガンド